Atrial fibrillation (AF) is the most common tachyarrhythmia in adults. The prevalence of AF increases with age. AF is associated with increased morbidity and mortality due to heart failure, stroke, and systemic thromboembolism. Recent European Society of Cardiology (ESC) guidelines recommend that antithrombotic therapy should be based on the presence (or absence) of risk factors for stroke and thrombo-embolism in AF patients. Before initiating anticoagulant therapy in AF patients, bleeding risks must also be evaluated. Warfarin is the most effective antithrombotic drug for the prevention of stroke and thrombo-embolism in AF patients with a high risk of thrombo-embolism. However, the management of warfarin use is very difficult because of its narrow therapeutic INR range and interactions with other drugs and foods. New oral anticoagulants, which can be administered as a fixed dose and do not require blood tests, can now be used as an alternative to warfarin.
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